Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I) Diefenbach, C., Hong, F., Ambinder, R. F., Cohen, J. B., Robertson, M., David, K. A., Advani, R. H., Fenske, T. S., Barta, S., Palmisano, N., Svoboda, J., Morgan, D., Karmali, R., Kahl, B. S., Ansell, S. M. AMER SOC HEMATOLOGY. 2018
View details for DOI 10.1182/blood-2018-99-115390
View details for Web of Science ID 000454837602057